Pathobiology of Secondary Immune Thrombocytopenia

Seminars in Hematology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Cines, Douglas B ^a   Liebman, Howard ^b   Stasi, Roberto ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; FC RECEPTOR; THROMBOPOIETIN;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; COMORBIDITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LYMPHOPROLIFERATIVE DISEASE; PORTAL HYPERTENSION; PRIORITY JOURNAL; THROMBOCYTOPOIESIS; VACCINATION;

HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 60549085053     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.12.005     Document Type: Article

References (186)

1. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 346 (2002) 995-1008
2. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88 (1996) 3-40
3. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120 (2003) 574-596
4. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111 (2008) 981-986
5. Martin D.I., Zon L.I., Mutter G., and Orkin S.H. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 344 (1990) 444-447
6. Tsang A.P., Visvader J.E., Turner C.A., Fujiwara Y., Yu C., Weiss M.J., et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90 (1997) 109-119
7. Roth G.J., Yagi M., and Bastian L.S. The platelet glycoprotein Ib-V-IX system: regulation of gene expression. Stem Cells 14 Suppl 1 (1996) 188-193
8. Hodohara K., Fujii N., Yamamoto N., and Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 95 (2000) 769-775
9. Broudy V.C., Lin N.L., and Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85 (1995) 1719-1726
10. Kaushansky K., Broudy V.C., Lin N., Jorgensen M.J., McCarty J., Fox N., et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A 92 (1995) 3234-3238
11. Gurney A.L., Wong S.C., Henzel W.J., and de Sauvage F.J. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A 92 (1995) 5292-5296
12. Bacon C.M., Tortolani P.J., Shimosaka A., Rees R.C., Longo D.L., and O'Shea J.J. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett 370 (1995) 63-68
13. Tortolani P.J., Johnston J.A., Bacon C.M., McVicar D.W., Shimosaka A., Linnekin D., et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 85 (1995) 3444-3451
14. Drachman J.G., Sabath D.F., Fox N.E., and Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 89 (1997) 483-492
15. Nagata Y., and Todokoro K. Thrombopoietin induces activation of at least two distinct signaling pathways. FEBS Lett 377 (1995) 497-501
16. Nakao T., Geddis A.E., Fox N.E., and Kaushansky K. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7 (2008) 257-266
17. Chanprasert S., Geddis A.E., Barroga C., Fox N.E., and Kaushansky K. Thrombopoietin (TPO) induces c-myc expression through a. Cell Signal 18 (2006) 1212-1218
18. Battinelli E.M., Hartwig J.H., and Italiano Jr. J.E. Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol 14 (2007) 419-426
19. Cines D.B., and McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 511-514
20. Tavassoli M., and McMillan R. Structure of the spleen in idiopathic thrombocytopenic purpura. Am J Clin Pathol 64 (1975) 180-191
21. Handin R.I., and Stossel T.P. Phagocytosis of antibody-coated platelets by human granulocytes. N Engl J Med 290 (1974) 989-993
22. McMillan R., Longmire R.L., Tavassoli M., Armstrong S., and Yelenosky R. In vitro platelet phagocytosis by splenic leukocytes in idiopathic thrombocytopenic purpura. N Engl J Med 290 (1974) 249-251
23. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 37 (2000) 239-248
24. He R., Reid D.M., Jones C.E., and Shulman N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 83 (1994) 1024-1032
25. Stasi R., Cooper N., Del Poeta G., Stipa E., Laura E.M., Abruzzese E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112 (2008) 1147-1150
26. Stasi R., Del Poeta G., Stipa E., Evangelista M.L., Trawinska M.M., Cooper N., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110 (2007) 2924-2930
27. Ho-Yen D.O., Hardie R., and Sommerville R.G. Varicella-induced thrombocytopenia. J Infect 8 (1984) 274-276
28. Solanilla A., Pasquet J.M., Viallard J.F., Contin C., Grosset C., Dechanet-Merville J., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 105 (2005) 215-218
29. Nagahama M., Nomura S., Kanazawa S., Ozaki Y., Kagawa H., and Fukuhara S. Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura. Eur J Haematol 69 (2002) 303-308
30. Roark J.H., Bussel J.B., Cines D.B., and Siegel D.L. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 100 (2002) 1388-1398
31. Olsson B., Ridell B., Carlsson L., Jacobsson S., and Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 112 (2008) 1078-1084
32. Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 (2003) 1123-1124
33. Zhang F., Chu X., Wang L., Zhu Y., Li L., Ma D., et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76 (2006) 427-431
34. Stoll D., Cines D.B., Aster R.H., and Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 65 (1985) 584-588
35. McMillan R., Wang L., Tomer A., Nichol J., and Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 103 (2004) 1364-1369
36. Ballem P.J., Segal G.M., Stratton J.R., Gernsheimer T., Adamson J.W., and Slichter S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80 (1987) 33-40
37. Nagata Y., Shozaki Y., Nagahisa H., Nagasawa T., Abe T., and Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 77 (1997) 808-814
38. Kosugi S., Kurata Y., Tomiyama Y., Tahara T., Kato T., Tadokoro S., et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 93 (1996) 704-706
39. Emmons R.V., Reid D.M., Cohen R.L., Meng G., Young N.S., Dunbar C.E., et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87 (1996) 4068-4071
40. Chang M., Nakagawa P.A., Williams S.A., Schwartz M.R., Imfeld K.L., Buzby J.S., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102 (2003) 887-895
41. Houwerzijl E.J., Blom N.R., van der Want J.J., Esselink M.T., Koornstra J.J., Smit J.W., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 103 (2004) 500-506
42. Nossent J.C., and Swaak A.J. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 80 (1991) 605-612
43. Kuwana M., Okazaki Y., Kajihara M., Kaburaki J., Miyazaki H., Kawakami Y., et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 46 (2002) 2148-2159
44. Ziakas P.D., Routsias J.G., Giannouli S., Tasidou A., Tzioufas A.G., and Voulgarelis M. Suspects in the tale of lupus-associated thrombocytopenia. Clin Exp Immunol 145 (2006) 71-80
45. Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl (2008) 3-8
46. Arnal C., Piette J.C., Leone J., Taillan B., Hachulla E., Roudot-Thoraval F., et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29 (2002) 75-83
47. Stasi R., Stipa E., Masi M., Oliva F., Sciarra A., Perrotti A., et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 84 (1994) 4203-4208
48. Diz-Kucukkaya R., Hacihanefioglu A., Yenerel M., Turgut M., Keskin H., Nalcaci M., et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98 (2001) 1760-1764
49. Dash S., Marwaha R.K., and Mohanty S. Lupus anticoagulant in immune thrombocytopenic purpura. Indian J Pediatr 71 (2004) 505-507
50. Bidot C.J., Jy W., Horstman L.L., Ahn E.R., Yaniz M., and Ahn Y.S. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 81 (2006) 391-396
51. Bidot C.J., Jy W., Horstman L.L., Ahn E.R., Jimenez J.J., Yaniz M., et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol 128 (2006) 366-372
52. Galli M., Daldossi M., and Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 71 (1994) 571-575
53. Macchi L., Rispal P., Clofent-Sanchez G., Pellegrin J.L., Nurden P., Leng B., et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 98 (1997) 336-341
54. Godeau B., Piette J.C., Fromont P., Intrator L., Schaeffer A., and Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 98 (1997) 873-879
55. Fabris F., Steffan A., Cordiano I., Borzini P., Luzzatto G., Randi M.L., et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 53 (1994) 232-236
56. Liebman H.A., and Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 557-573
57. Pennings M.T., Derksen R.H., Urbanus R.T., Tekelenburg W.L., Hemrika W., and De Groot P.G. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost 5 (2007) 1538-1544
58. Pennings M.T., Derksen R.H., van L.M., Adelmeijer J., Vanhoorelbeke K., Urbanus R.T., et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 5 (2007) 369-377
59. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 54 (2006) 2558-2567
60. Nojima J., Suehisa E., Kuratsune H., Machii T., Koike T., Kitani T., et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus-possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 81 (1999) 436-441
61. Alliot C., Messouak D., Albert F., and Barrios M. Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome. Am J Hematol 68 (2001) 215
62. Alarcon-Segovia D., and Sanchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 16 (1989) 1359-1361
63. Cohen M.G., and Lui S.F. Multiple complications of the antiphospholipid syndrome with apparent response to aspirin therapy. J Rheumatol 19 (1992) 803-806
64. Panzer S., Haubenstock A., and Minar E. Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab 70 (1990) 491-496
65. Stiegler G., Stohlawetz P., Brugger S., Jilma B., Vierhapper H., Hocker P., et al. Elevated numbers of reticulated platelets in hyperthyroidism: direct evidence for an increase of thrombopoiesis. Br J Haematol 101 (1998) 656-658
66. Cordiano I., Betterle C., Spadaccino C.A., Soini B., Girolami A., and Fabris F. Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes?. Clin Exp Immunol 113 (1998) 373-378
67. Ioachimescu A.G., Makdissi A., Lichtin A., and Zimmerman R.S. Thyroid disease in patients with idiopathic thrombocytopenia: a cohort study. Thyroid 17 (2007) 1137-1142
68. Pratt E.L., Tarantino M.D., Wagner D., Hirsch Pescovitz O., Bowyer S., and Shapiro A.D. Prevalence of elevated antithyroid antibodies and antinuclear antibodies in children with immune thrombocytopenic purpura. Am J Hematol 79 (2005) 175-179
69. Pegels J.G., Helmerhorst F.M., van Leeuwen E.F., van de Plas-van Dalen C., Engelfriet C.P., and von dem Borne A.E. The Evans syndrome: characterization of the responsible autoantibodies. Br J Haematol 51 (1982) 445-450
70. Miller B.A., and Shultz Beardsley D. Autoimmune pancytopenia of childhood associated with multisystem disease manifestations. J Pediatr 103 (1983) 877-881
71. Wang W., Herrod H., Pui C.H., Presbury G., and Wilimas J. Immunoregulatory abnormalities in Evans syndrome. Am J Hematol 15 (1983) 381-390
72. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81 (1995) 935-946
73. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A., et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268 (1995) 1347-1349
74. Le Deist F., Emile J.F., Rieux-Laucat F., Benkerrou M., Roberts I., et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348 (1996) 719-723
75. Rieux-Laucat F., Le Deist F., and Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ 10 (2003) 124-133
76. Teachey D.T., Manno C.S., Axsom K.M., Andrews T., Choi J.K., Greenbaum B.H., et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105 (2005) 2443-2448
77. Hamblin T.J., Oscier D.G., and Young B.J. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39 (1986) 713-716
78. Dhodapkar M.V., Li C.Y., Lust J.A., Tefferi A., and Phyliky R.L. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. Blood 84 (1994) 1620-1627
79. Xiros N., Binder T., Anger B., Bohlke J., and Heimpel H. Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin's disease. Eur J Haematol 40 (1988) 437-441
80. Landgren O., Engels E.A., Pfeiffer R.M., Gridley G., Mellemkjaer L., Olsen J.H., et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 98 (2006) 1321-1330
81. Martinelli G., Zinzani P.L., Magagnoli M., Vianelli N., and Tura S. Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission. Haematologica 83 (1998) 669-670
82. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33 (2006) 230-239
83. Montillo M., Tedeschi A., and Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 15 (1994) 187-188
84. Ergas D., Tsimanis A., Shtalrid M., Duskin C., and Berrebi A. T-gamma large granular lymphocyte leukemia associated with amegakaryocytic thrombocytopenic purpura, Sjogren's syndrome, and polyglandular autoimmune syndrome type II, with subsequent development of pure red cell aplasia. Am J Hematol 69 (2002) 132-134
85. Lai D.W., Loughran Jr. T.P., Maciejewski J.P., Sasu S., Song S.X., Epling-Burnette P.K., et al. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res 32 (2008) 823-827
86. Morris L., Distenfeld A., Amorosi E., and Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med 96 (1982) 714-717
87. Walsh C.M., Nardi M.A., and Karpatkin S. On the mechanism of thrombocytopenic purpura in sexually active homosexual men. N Engl J Med 311 (1984) 635-639
88. Abrams D.I., Kiprov D.D., Goedert J.J., Sarngadharan M.G., Gallo R.C., and Volberding P.A. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med 104 (1986) 47-50
89. Murphy M.F., Metcalfe P., Waters A.H., Carne C.A., Weller I.V., Linch D.C., et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 66 (1987) 337-340
90. Zon L.I., Arkin C., and Groopman J.E. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 66 (1987) 251-256
91. Ballem P.J., Belzberg A., Devine D.V., Lyster D., Spruston B., Chambers H., et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 327 (1992) 1779-1784
92. Landonio G., Nosari A., Spinelli F., Vigorelli R., Caggese L., and Schlacht I. HIV-related thrombocytopenia: four different clinical subsets. Haematologica 77 (1992) 398-401
93. Najean Y., and Rain J.D. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 123 (1994) 415-420
94. Bahner I., Kearns K., Coutinho S., Leonard E.H., and Kohn D.B. Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 90 (1997) 1787-1798
95. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 198;91:1479-95.
96. Kowalska M.A., Ratajczak J., Hoxie J., Brass L.F., Gewirtz A., Poncz M., et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 104 (1999) 220-229
97. Sato T., Sekine H., Kakuda H., Miura N., Sunohara M., and Fuse A. HIV infection of megakaryocytic cell lines. Leuk Lymphoma 36 (2000) 397-404
98. Zucker-Franklin D., Seremetis S., and Zheng Z.Y. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood 75 (1990) 1920-1923
99. Sakaguchi M., Sato T., and Groopman J.E. Human immunodeficiency virus infection of megakaryocytic cells. Blood 77 (1991) 481-485
100. Zucker-Franklin D., and Cao Y.Z. Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. Proc Natl Acad Sci U S A 86 (1989) 5595-5599
101. Zucker-Franklin D., Termin C.S., and Cooper M.C. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol 134 (1989) 1295-1303
102. Karpatkin S., Nardi M.A., and Hymes K.B. Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients. Proc Natl Acad Sci U S A 92 (1995) 2263-2267
103. Li Z., Nardi M.A., and Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 106 (2005) 572-576
104. Bettaieb A., Fromont P., Louache F., Oksenhendler E., Vainchenker W., Duedari N., et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood 80 (1992) 162-169
105. Hohmann A.W., Booth K., Peters V., Gordon D.L., and Comacchio R.M. Common epitope on HIV p24 and human platelets. Lancet 342 (1993) 1274-1275
106. Nardi M., Tomlinson S., Greco M.A., and Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 106 (2001) 551-561
107. Karpatkin S., Nardi M., Lennette E.T., Byrne B., and Poiesz B. Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts. Proc Natl Acad Sci U S A 85 (1988) 9763-9767
108. Karpatkin S., and Nardi M. Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia. J Clin Invest 89 (1992) 356-364
109. Koefoed K., and Ditzel H.J. Identification of talin head domain as an immunodominant epitope of the antiplatelet antibody response in patients with HIV-1-associated thrombocytopenia. Blood 104 (2004) 4054-4062
110. Rajan S.K., Espina B.M., and Liebman H.A. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 129 (2005) 818-824
111. Pyrsopoulos N.T., and Reddy K.R. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 3 (2001) 71-78
112. Pockros P.J., Duchini A., McMillan R., Nyberg L.M., McHutchison J., and Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 97 (2002) 2040-2045
113. Yabu K., Kiyosawa K., Ako S., Usuda S., Yoshizawa K., Tanaka E., et al. Type C chronic hepatitis associated with thrombocytopenia in two patients. J Gastroenterol Hepatol 9 (1994) 99-104
114. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 45 (1966) 645-657
115. Espanol I., Gallego A., Enriquez J., Rabella N., Lerma E., Hernandez A., et al. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. Hepatogastroenterology 47 (2000) 1404-1406
116. Adinolfi L.E., Giordano M.G., Andreana A., Tripodi M.F., Utili R., Cesaro G., et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 113 (2001) 590-595
117. Jiang X.H., Xie Y.T., and Tan D.M. [Study on the influencing factors of thrombocytopenia in viral hepatitis]. Zhonghua Gan Zang Bing Za Zhi 12 (2004) 734-736
118. Peck-Radosavljevic M., Zacherl J., Meng Y.G., et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. J Hepatol 27 (1997) 127-131
119. Goulis J., Chau T.N., Jordan S., Mehta A.B., Watkinson A., Rolles K., et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 44 (1999) 754-758
120. Panzer S., Seel E., Brunner M., Kormoczi G.F., Schmid M., Ferenci P., et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 77 (2006) 513-517
121. Hamaia S., Li C., and Allain J.P. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 98 (2001) 2293-2300
122. Kajihara M., Kato S., Okazaki Y., Kawakami Y., Ishii H., Ikeda Y., et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 37 (2003) 1267-1276
123. Doi T., Homma H., Mezawa S., Kato J., Kogawa K., Sakamaki S., and Niitsu Y. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 24 (2002) 23
124. Zhang W, Nardi MA, Borkowsky W, Karpatkin S. Role of molecular mimicry of hepatitis C virus (HCV) protein with platelet GPIIIa in hepatitis-C related immunologic thrombocytopenia. Blood. In press.
125. Bordin G., Ballare M., Zigrossi P., Bertoncelli M.C., Paccagnino L., Baroli A., et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion?. Clin Exp Rheumatol 13 Suppl 13 (1995) S39-S43
126. de Almeida A.J., Campos-de-Magalhaes M., de Melo Marcal O.P., et al. Hepatitis C virus-associated thrombocytopenia: a controlled prospective, virological study. Ann Hematol 83 (2004) 434-440
127. Iga D., Tomimatsu M., Endo H., Ohkawa S., and Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 75 (2005) 417-423
128. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 14 Suppl D (2000) :60D-6D
129. McHutchison J.G., Dusheiko G., Shiffman M.L., Rodriguez-Torres M., Sigal S., Bourliere M., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357 (2007) 2227-2236
130. Michel M., Cooper N., Jean C., Frissora C., and Bussel J.B. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood 103 (2004) 890-896
131. Gasbarrini A., Franceschi F., Tartaglione R., Landolfi R., Pola P., and Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352 (1998) 878
132. Maeda S., Ogura K., Yoshida H., Kanai F., Ikenoue T., Kato N., et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 42 (1998) 338-343
133. Maeda S., Yoshida H., Ikenoue T., Ogura K., Kanai F., Kato N., et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut 44 (1999) 336-341
134. Emilia G., Luppi M., Zucchini P., Morselli M., Potenza L., Forghieri F., et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 110 (2007) 3833-3841
135. Franceschi F., Christodoulides N., Kroll M.H., and Genta R.M. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med 140 (2004) 766-767
136. Takahashi T., Yujiri T., Shinohara K., Inoue Y., Sato Y., Fujii Y., et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 124 (2004) 91-96
137. Gerhard M., Rad R., Prinz C., and Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter 7 Suppl 1 (2002) 17-23
138. Byrne M.F., Kerrigan S.W., Corcoran P.A., Atherton J.C., Murray F.E., Fitzgerald D.J., et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 124 (2003) 1846-1854
139. Cines D.B. Inside Blood; ITP: time to "bug off"?. Blood 110 (2007) 3818-3819
140. Asahi A., Nishimoto T., Okazaki Y., Suzuki H., Masaoka T., Kawakami Y., et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 118 (2008) 2939-2949
141. Veneri D., De Matteis G., Solero P., Federici F., Zanuso C., Guizzardi E., et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 16 (2005) 307-311
142. Stasi R., Rossi Z., Stipa E., Amadori S., Newland A.C., and Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 118 (2005) 414-419
143. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., and Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 84 (2001) 227-229
144. Abramson J.S., and Pickering L.K. US immunization policy. JAMA 287 (2002) 505-509
145. Black C., Kaye J.A., and Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 55 (2003) 107-111
146. Schattner A. Consequence or coincidence?. The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23 (2005) 3876-3886
147. Neau D., Bonnet F., Michaud M., Perel Y., Longy-Boursier M., Ragnaud J.M., et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis 30 (1998) 115-118
148. Naidu S., Messmore H., Caserta V., and Fine M. CNS lesions in neonatal isoimmune thrombocytopenia. Arch Neurol 40 (1983) 552-554
149. Beeler J., Varricchio F., and Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 15 (1996) 88-90
150. Nieminen U., Peltola H., Syrjala M.T., Makipernaa A., and Kekomaki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 82 (1993) 267-270
151. Jadavji T., Scheifele D., and Halperin S. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J 22 (2003) 119-122
152. Chou A.L., Huang W.W., Tsao S.M., Li C.T., and Su C.C. Human herpesvirus type 8 in patients with cirrhosis: correlation with sex, alcoholism, hepatitis B virus, disease severity, and thrombocytopenia. Am J Clin Pathol 130 (2008) 231-237
153. Hui D.S. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. Respirology 13 Suppl 1 (2008) S10-S13
154. Rafailidis P.I., Mourtzoukou E.G., Varbobitis I.C., and Falagas M.E. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 5 (2008) 47
155. Yang M., Ng M.H., and Li C.K. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology 10 (2005) 101-105
156. Vipan W. Quinine as a cause of purpura. Lancet 2 (1865) 37
157. Drug-induced thrombocytopenia. http://moon.ouhsc.edu/jgeorge/DITP.html Accessed September 11, 2008
158. Aster R.H., and Bougie D.W. Drug-induced immune thrombocytopenia. N Engl J Med 357 (2007) 580-587
159. van den Bemt P.M., Meyboom R.H., and Egberts A.C. Drug-induced immune thrombocytopenia. Drug Saf 27 (2004) 1243-1252
160. Visentin G.P., Newman P.J., and Aster R.H. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 77 (1991) 2668-2676
161. Asvadi P., Ahmadi Z., and Chong B.H. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 102 (2003) 1670-1677
162. Parker C.W. Hapten immunology and allergic reactions in humans. Arthritis Rheum 24 (1981) 1024-1036
163. Bougie D.W., Wilker P.R., and Aster R.H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 108 (2006) 922-927
164. Aster R.H. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127 (2005) 53S-59S
165. McCorry R.B., and Johnston P. Fatal delayed thrombocytopenia following abciximab therapy. J Invasive Cardiol 18 (2006) E173-E174
166. Curtis B.R., Swyers J., Divgi A., McFarland J.G., and Aster R.H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99 (2002) 2054-2059
167. Tcheng J.E., Kereiakes D.J., Lincoff A.M., George B.S., Kleiman N.S., Sane D.C., et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104 (2001) 870-875
168. Curtis B.R., Divgi A., Garritty M., and Aster R.H. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2 (2004) 985-992
169. von dem Borne A.E., Pegels J.G., van der Stadt R.J., van der Plas-van Dalen C.M., and Helmerhorst F.M. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?. Br J Haematol 63 (1986) 509-516
170. Garner S.F., Campbell K., Metcalfe P., Keidan J., Huiskes E., Dong J.F., et al. Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 100 (2002) 344-346
171. George J.N., Raskob G.E., Shah S.R., Rizvi M.A., Hamilton S.A., Osborne S., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129 (1998) 886-890
172. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004) 361-369
173. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
174. Lubenow N., Kempf R., Eichner A., Eichler P., Carlsson L.E., and Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122 (2002) 37-42
175. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
176. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
177. Reilly M.P., Taylor S.M., Hartman N.K., Arepally G.M., Sachais B.S., Cines D.B., et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 98 (2001) 2442-2447
178. Rauova L., Poncz M., McKenzie S.E., Reilly M.P., Arepally G., Weisel J.W., et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105 (2005) 131-138
179. Rauova L., Zhai L., Kowalska M.A., Arepally G.M., Cines D.B., and Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107 (2006) 2346-2353
180. Cines D.B., Tomaski A., and Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316 (1987) 581-589
181. Arepally G.M., and Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98 (2001) 1252-1254
182. Thachil J. Heparin induced thrombocytopenia with thrombosis: a two step process?. Hematology 13 (2008) 181-182
183. Bauer T.L., Arepally G., Konkle B.A., Mestichelli B., Shapiro S.S., Cines D.B., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95 (1997) 1242-1246
184. Warkentin T.E., Sheppard J.I., Moore J.C., Sigouin C.S., and Kelton J.G. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6 (2008) 1304-1312
185. Greinacher A., Eichler P., Lubenow N., and Kiefel V. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol 5 (2001) 166-200
186. Liebman H. Other immune thrombocytopenias. Semin Hematol 44 (2007) S24-S34